FDA Can Regulate Stem Cell Treatments, DC Circ. Rules

The D.C. Circuit on Tuesday ruled that Regenerative Sciences LLC's stem cell treatment is a drug and therefore subject to U.S. Food and Drug Administration regulations, rejecting the company's claims that its...

Already a subscriber? Click here to view full article